Search
United Therapeutics Corp
UTHRAdd to Watchlist
500.350USD
-2.350-0.47%
Close 09-15 16:00（ET）
21.35BMarket Cap
17.09P/E TTM
United Therapeutics Corp (UTHR) Stock Price Target & Forecast
Analyst Rating
Based on 16 analysts giving stock ratings to United Therapeutics Corp in the past month.
Buy
4 Strong Buy
9 Buy
3 Hold
0 Sell
0 Strong Sell
Target Price
652.378USD+31.23%
UTHR Analyst Recommendation Trends
In the current month, UTHR has received 9 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. UTHR average Analyst price target in the last month is 652.378.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
4
4
4
4
5
5
5
5
9
9
9
9
7
6
6
5
3
3
3
3
4
4
4
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16
16
16
16
16
15
15
15
UTHR Analyst Rating for Peer Comparison
Updated: Sep 15, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Amgen Inc
AMGN
4
12
18
2
1
37
Biogen Inc
BIIB
7
17
12
1
0
37
Eli Lilly and Co
LLY
10
17
6
1
0
34
AbbVie Inc
ABBV
8
19
6
0
0
33
Pfizer Inc
PFE
5
6
19
1
1
32
Merck & Co Inc
MRK
8
14
10
0
0
32
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Vertex Pharmaceuticals Inc
VRTX
9
16
5
0
1
31
Regeneron Pharmaceuticals Inc
REGN
6
14
10
0
0
30
Alnylam Pharmaceuticals Inc
ALNY
5
18
7
0
0
30
Financial Forecasting
Based on analysts' estimates, UTHR EPS is projected to reach 6.430 in FY2026Q3, following reported EPS of 7.817 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
7.19
6.87
6.83
6.43
6.79
Actual
8.39
6.32
7.82
--
--
Surprise
+16.81%
-7.99%
+14.41%
--
--
FAQs
What is United Therapeutics Corp's expected revenue for the next quarter?
United Therapeutics Corp's expected revenue is 790.86M.
What is United Therapeutics Corp's price target?
Analysts forecast that United Therapeutics Corp's price target is USD 652.38, with the highest forecast at USD 725.00 and the lowest forecast at USD 515.00.
How have United Therapeutics CorpUTHR's recent earnings per share performed?
The market expectation was USD 7.82, while United Therapeutics CorpUTHR's earnings per share (EPS) for the previous quarter was USD 6.32. EPS for the next quarter is expected at USD 6.43.
What is the analyst rating for United Therapeutics Corp?
Based on the ratings of United Therapeutics Corp's stock from 16 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.